Article Text


OP0053 Success-1 in osteoarthritis (oa) trial: celecoxib significantly reduces risk of serious upper gi complications compared to nsaids while providing similar efficacy in 13,274 randomised patients
  1. G Singh1,
  2. J Goldstein2,
  3. W Bensen3,
  4. N Agrawal4,
  5. G Eisen5,
  6. J Fort6,
  7. A Bello6,
  8. S Boots6
  1. 1Department of Medicine, Stanford University, Palo Alto
  2. 2University of Illinois at Chicago, Chicago
  3. 3McMaster University/St. Joseph’s Hospital, Hamilton, Canada
  4. 4Duke University, Durham
  5. 5Vanderbilt University of Medicine, Nashville
  6. 6Pharmacia, Peapack, USA


Background SUCCESS-1, the largest double-blind, randomised study in rheumatology, compared 2 therapeutic doses of celecoxib to conventional doses of NSAIDs in a trial designed to closely parallel clinical practice in various worldwide settings.

Objectives To compare the efficacy, safety, and tolerability of celecoxib 200 or 400 mg/d and NSAIDs in OA of the knee, hip, and hand.

Methods SUCCESS-1 enrolled 13,274 patients with OA from 1142 centres in 39 countries. Patients were randomised to: celecoxib 200 mg/d, celecoxib 400 mg/d, or NSAID (naproxen 100 mg/d in US/Canada, diclofenac 100 mg/d in other 37 countries). Efficacy assessments, stratified by country/subregion, included patient and physician global assessments, pain scale, night pain, and WOMAC. An independent Gastrointestinal Events Committee (GEC) categorised potential clinically significant upper GI (UGI) events in a blinded fashion as ulcer complications (perforations, gastric outlet obstruction, bleeding) or symptomatic ulcerations.

Results Of 13,194 patients treated, 4393 and 4407 received 200 or 400 mg/d of celecoxib, respectively, 905 received naproxen 1000 mg/d, and 3489 received diclofenac 100 mg/d. Most patients were female (67%); mean age was 62 years. Baseline aspirin use and UGI bleeding history were comparable. Efficacy results between the 2 celecoxib doses and naproxen or diclofenac were comparable for most countries/subregions. UGI events (dyspepsia, abdominal pain, and nausea) were significantly reduced in celecoxib- compared to naproxen- or diclofenac-treated patients. Of 144 possible serious UGI GEC-referred events, 9 met strict ulcer complication definition and 36 patients had confirmed ulcer complications and/or symptomatic ulcers.

Abstract OP0053 Table 1

Conclusion Compared to conventional NSAIDs, celecoxib reduced the risk of ulcer complications by almost 87.5%, while providing equivalent efficacy and better tolerability. Sponsored by Pharmacia Corporation and Pfizer Inc.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.